Webinar Leaders

House Speaker

Charlotte Price
 Research Analyst
 Beacon Targeted Therapies


Frank Plowden
Account Manager
Beacon Targeted Therapies

This webinar covers

  • A overview of the DDR therapeutic landscape, with coverage of the first generation of approved PARP inhibitors.
  • A detailed look at the preclinical and clinical “second generation” DDR assets, including; specialized PARP-targeted assets, ATR, and WEE1 inhibitors.
  • A review of a third generation of novel DDR targets, including POL-θ, WRN, and PARG.
  • Have the opportunity to ask your questions about the landscape and the direction in which it is headed.
Hosted by


Speak with our team about Beacon DDR

What is Beacon DDR?

Beacon DDR Logo


Beacon DNA Damage Response (DDR) covers trial and drug records for clinical, preclinical, approved and discontinued therapeutics targeting key points in DNA damage response pathways.

This module identifies drugs utilizing the concept of synthetic lethality, and covers DDR repair pathway components, including:

  • Damage Sensors
  • Signalling/Mediator Proteins
  • Effector Proteins
  • Cell Cycle Checkpoints
  • DNA Metabolism when in relation to repair and recombination

Find out More

Our DDR Team

Charlotte Price – Research Analyst

Frank Plowden

Frank Plowden – Account Manager


Will Savill – Account Manager

Contact Us

What is Beacon?

We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.

Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements

Find out more